Related Experiment Video
Updated: May 21, 2026
06:13
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
Published on: February 21, 2020
Low affinity GPCRs for metabolic intermediates: challenges for pharmacologists
1Molecular Cardiology, Victor Chang Cardiac Research Institute Darlinghurst, NSW, Australia. n.smith@victorchang.edu.au
Frontiers in Endocrinology
|June 1, 2012
Summary
Metabolites acting on G protein-coupled receptors offer new therapeutic targets for metabolic diseases. Researchers face challenges with low ligand affinity and selectivity, but strategies exist to overcome these obstacles.
Area of Science:
- Biochemistry
- Pharmacology
- Metabolism
Background:
- Metabolites and metabolic intermediates activate G protein-coupled receptors (GPCRs).
- This activation presents novel therapeutic targets for hypertension, type 2 diabetes, inflammation, and metabolic syndrome.
- Endogenous ligands for these GPCRs possess established metabolic functions, complicating drug development.
Purpose of the Study:
- To review challenges in studying metabolite-GPCR interactions.
- To highlight successful strategies for overcoming research obstacles.
- To discuss the implications for drug discovery and therapeutic targeting.
Main Methods:
- Literature review of research on metabolite-GPCRs.
- Analysis of challenges including low ligand affinity and poor selectivity.
- Synthesis of reported methods for enhancing ligand-receptor interaction studies.
Main Results:
- Low ligand affinity and lack of selectivity are significant hurdles.
- Established metabolic roles of endogenous ligands complicate targeted therapies.
- Various experimental and computational approaches have been developed to address these issues.
Conclusions:
- Despite challenges, metabolite-GPCRs represent a promising area for therapeutic intervention.
- Overcoming low affinity and selectivity is crucial for advancing drug discovery.
- Continued research into these systems will yield new treatments for metabolic and inflammatory diseases.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...